A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

NCT06465186 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis
NAFLD
Metabolic Dysfunction-associated Steatotic Liver Disease
Metabolic Dysfunction-associated Steatohepatitis

Interventions

COMBINATION_PRODUCT: Efinopegdutide
COMBINATION_PRODUCT: Placebo

Sponsor

Merck Sharp & Dohme LLC